Yong Yu - Feb 17, 2023 Form 4 Insider Report for GENELUX CORP (GNLX)

Role
VP, Clinical Trial Operations
Signature
/s/ Thomas Zindrick, Attorney-in-Fact
Stock symbol
GNLX
Transactions as of
Feb 17, 2023
Transactions value $
$0
Form type
4
Date filed
5/2/2023, 04:22 PM
Previous filing
Jan 25, 2023
Next filing
Aug 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNLX Common Stock Award $0 +9K +6% $0.00 159K Feb 17, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will be fully vested on July 25, 2023.